Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RDD1609 as a Treatment for Idiopathic Pruritus Ani: A Randomized Double Blinded Placebo Controlled Crossover Study

NCT03757403 is registered in ClinicalTrials.gov with RDD Pharma Ltd as lead sponsor.

NCT NCT03757403
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03757403 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
RDD1609 as a Treatment for Idiopathic Pruritus Ani: A Randomized Double Blinded Placebo Controlled Crossover Study
Lead sponsor
RDD Pharma Ltd
Phase
Phase 2
Overall status
Withdrawn
Start date
May 1, 2020
Completion date
December 31, 2020
Enrollment
0 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic pruritus ani